UroGen Pharma CFO Chris Degnan sells $80,791 in shares

UroGen Pharma's CFO, Chris Degnan, recently divested a portion of his company shares, selling 2,202 ordinary shares worth $80,791 on October 8, 2026. Despite UroGen Pharma's stock having gained 125% over the past year, a week's decline saw shares drop about 11%. The sale was made to fulfill tax obligations from the settlement of restricted stock units (RSUs).

Simultaneously, Degnan purchased 4,483 ordinary shares to settle his RSUs, which were part of a larger grant from October 8, 2024. This grant included 13,450 ordinary shares, which vest in three annual installments starting October 8, 2025. Currently, Degnan holds 4,561 ordinary shares and 4,484 restricted stock units in UroGen Pharma.

Meanwhile, UroGen Pharma reported a robust 2026 Q2 revenue of $72.5 million, exceeding analysts' expectations of $62.82 million. This growth was primarily fueled by ZUSDURI, its bladder-cancer drug, which generated $50.4 million in revenue, up 73% from the previous quarter. The company also reported $22.0 million in revenue from Jelmyto, with full-year guidance hovering between $97 million and $101 million.

UroGen Pharma has garnered positive attention from analysts with raised price targets and Buy ratings from firms like Guggenheim and Jefferies. The company has also filed an FDA New Drug Application for UGN-103, a mitomycin formulation for bladder cancer treatment, which bolstered its market prospects.